Home›Companies›Biotech & Pharma›Solstice Oncology

Solstice Oncology, Inc.

Develops cancer immunotherapy for patients before surgery, beginning with colon cancer.

Updated Nov 11, 2026·Latest SEC filing Mar 9, 2026·Suggest an edit

About Solstice Oncology

Solstice Oncology is a private company based in Boston, Massachusetts, incorporated in 2026 in Delaware. It has reported $121,260,306 raised in one offering on Form D since March 2026. Its chief executive is Caroline Loew.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Feb 20, 2026Mar 9, 2026$121,260,306of $298.4M target8$15.1MEquity, Options, Securities on exerciseRule 506(b)Form D ↗

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Solstice Oncology's Form D filed Mar 9, 2026.

AL
Andrew Levin
Director
Julie Grant
Julie Grant
Director
Emily Minkow
Emily Minkow
Director
CL
Caroline Loew
President & CEO, Solstice Oncology, director

Sources

  1. SECSolstice Oncology, Inc. filing history